First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate

Br J Haematol. 2014 Oct;167(1):139-41. doi: 10.1111/bjh.12937. Epub 2014 May 10.
No abstract available

Keywords: chronic myeloid leukaemia; efficacy; generic; imatinib mesylate.

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Benzamides / therapeutic use*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myeloid, Chronic-Phase / drug therapy*
  • Piperazines / therapeutic use*
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate